Amid dangerously cold temperatures in the Kansas City region, the Community Services League’s Drop-In Center offers ...

Dr. Michael Osterholm, Director of the Center for Infectious Disease Research and Policy at the University of Minnesota joins ...

CSL (ASX:CSL) has posted its half-year results, delivering results that are best described as mixed. At the headline level, ...

The expectation of an increased tempo for the domestic football league, tactical changes brought by foreign coaches and how ...

The ASX-listed giant says it can switch manufacturing sites if Donald Trump imposes tariffs on pharmaceuticals. It expects ...

The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...

CSL's latest dividend should be turning investors' heads... The post Everything you need to know about the latest CSL ...

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

The CSL Ltd (ASX: CSL) share price will be watched closely today after the biotech giant released its half year ...

CSL has reported a 7% net profit rise for the December half, with its blood-derived products offsetting weak flu vaccination ...

CSL Seqirus, the vaccination segment, was affected by low influenza vaccination rates in the US, dragging down overall ...